ArticleAlimentary pharmacology & therapeutics2026
Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Outcomes for a digital prescription mobile application for adults with irritable bowel syndrome: an uncontrolled trial.BMC gastroenterology · 2026Trial
- Exploring Sex Differences in Irritable Bowel Syndrome Prevalence, Environmental Risk, and Comorbidities: A Population-Based Cohort Study of Veterans.Clinical and translational gastroenterology · 2026Observational
- Irritable Bowel Syndrome in Inflammatory Bowel Disease: An Evidence-Based Practical Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe United Kingdom (UK) has one of the highest worldwide opioid prescription rates per capita. International guidelines caution against the use of opioids for chronic non-malignant pain, including irritable bowel syndrome (IBS).
aimsTo study the prevalence and impact of regular opioid use among people with Rome IV IBS in community settings in the UK.
methodsWe collected demographic, quality of life (QoL), psychological symptoms, and healthcare utilisation data from 752 people with Rome IV IBS. Participants were recruited via electronic mailshot in July 2021 through ContactME-IBS, a UK registry of persons diagnosed with IBS primarily by a general practitioner or gastroenterologist.
resultsAmong participants, 148 (19.7%) reported taking an opioid regularly. The prevalence of opioid use did not vary across IBS subtypes (p = 0.10). Disease-specific and generic QoL were lower among opioid users than non-users (p < 0.001, both analyses). Compared with non-users, a greater proportion of opioid users had anxiety or depression (p < 0.001, both analyses) and greater overall activity impairment (p < 0.001). The direct healthcare costs related to investigations (p = 0.003), IBS-related medications (p < 0.001), and unplanned hospital attendances (p < 0.001) were greater among participants who used opioids. Opioid users also expressed a greater willingness to accept the risk of death in return for a cure of IBS symptoms from a hypothetical medication (p = 0.002).
conclusionApproximately one in five people with Rome IV IBS used opioids on a regular basis. Compared with non-users, opioid users had worse QoL, greater psychological impairment, and higher direct healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.